Pterygium and its management
-
Upload
anjalihiroli87 -
Category
Education
-
view
6.933 -
download
2
Transcript of Pterygium and its management
![Page 1: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/1.jpg)
PTERYGIUM AND ITS MANAGEMENT
MODERATOR: DR SURESH.H.H PRESENTER:DR ANJALI
![Page 2: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/2.jpg)
Anatomy of conjunctiva
![Page 3: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/3.jpg)
Histology of normal conjunctiva
![Page 4: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/4.jpg)
Derived from Greek word ‘pterygion’ means wing.
It is a non malignant slow growing proliferation of wing shaped fibrovascular tissue.
Arises from subconjunctival tissue. May extend over the cornea thus disturbing
the vision.
DEFINITION- PTERYGIUM
![Page 5: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/5.jpg)
World wide distribution.
More common in warm and dry climates.
Prevalence : 22% equatorial areas.
<2% in latitudes between
28-38degree.
Direct relation with amount of UV exposure.
EPIDEMIOLOGY
![Page 6: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/6.jpg)
Sex: male : female= 2:1
Age:>40years high prevalence
20-40years high incidence.
In India prevalence is 9.5%.
Morbidity: causes significant alteration in
visual function in advanced cases.
![Page 7: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/7.jpg)
Strong association between UV light exposure and formation of pterygium.
More common- in patients who worked outdoors.
In welders than other factory workers. Also associated with basal cell carcinoma,
porphyria cutanea tarda, polymorphous light eruptions, xeroderma pigmentosa.
ETIOPATHOGENESIS.
![Page 8: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/8.jpg)
ANGIOGENESIS FACTOR:Prolonged UV
exposure causes biological changes in the
bowmans membrane.
Altered protein so formed could act as
angiogenic/ pterygiogenic factor.
![Page 9: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/9.jpg)
UV Exposure: May induce hyperplasia in limbal
cells. These altered cells invade the cornea and
limbus which moves centripetally with them.
This explains wing shape of the pterygium.
UV radiation causes depletion of langerhan
cells at limbus.(stocker’s line).
![Page 10: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/10.jpg)
Exposure to UVB+altered tear film
Injury and susceptibility
Loss of collagenase and dehydration
Accumulation of Extracellular matrix
Antigenic,type1 HS Pinguecula Fibroblastic reaction Inflammation PTERYGIUM PTERYGIUM
![Page 11: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/11.jpg)
Light entering the temporal limbus at
90degree is concentrated at medial limbus.
Related to corneal curvature.
This explains the predominance of medial
pterygium.
ALBEDO HYPOTHESIS
![Page 12: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/12.jpg)
Dry and dusty environment.
Drying of the tear film by wind devitalizes
tissue of medial 3rd of the palpebral
aperture.
This allows the actinic radiation to damage
the conjunctival, corneal epithelium and
bowmans membrane.
![Page 13: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/13.jpg)
MICROTRAUMA: mechanical irritation by dust particles, enhanced by tear flow from lateral to medial.
IMMUNOLOGY: Cell bound IgE irritant complexes initiate the release of inflammatory mediators from mast cells.
Release of stimulatory factors. Development of pterygium.
![Page 14: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/14.jpg)
Expression of vimentin. P53 mutation leads to decreased
apoptosis and increased TGF-b which leads to increased growth.
RECURRENT PTERYGIUM- stem cells are more scattered and expression pattern is more denser.
Genetic predisposition
![Page 15: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/15.jpg)
HYPOXIA: increase in non perfusion areas and attenuated vessels in nasal limbus during early stage of pterygium causes recruitment of progenitor cells.
Viral markers: infection with HPV and herpes virus is considered as risk factor(rare).
![Page 16: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/16.jpg)
Elastotic degeneration of collagen.(Not a true elastic tissue)
Fibro vascular proliferation with an overlying covering of epithelium-characterized by Cellular proliferation.
Tissue remodeling. Neovascularisation.
Subepithelial tissue shows basophilic degeneration.
PATHOLOGY
![Page 17: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/17.jpg)
Destruction of bowman’s membrane in the cornea.
So there is residual corneal scarring when these growth are removed.
Epithelium shows secondary changes like orthokeratosis,acanthosis,dyskeratosis.
Mast cells occur in increased number.
![Page 18: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/18.jpg)
Histology
Normal conjunctiva Pterygium
![Page 19: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/19.jpg)
Histology
![Page 20: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/20.jpg)
CLINICAL STAGING PATHOLOGICAL STAGING
Stage I Exposure conjunctivitis
Size and number of Conjunctival vessels Mild – moderate congestionS/S of drynessNo formed lesions
Altered tear filmMild vascular response
Stage II Pinguecula and pterygium
Distinct raised lesion on bulbar conjunctivaWith or w/o abnormal vascularization and inflammation
Cell injuryInflammatory response
Clinical staging of pterygium
![Page 21: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/21.jpg)
Stage III Limbal pterygium
Head is on or across the limbus with or w/o an iron line at the conjunctival corneal interface
Vascularization and fibrous proliferationSymptoms more pronounced
Lesion organization
Mixed proliferation and degeneration
Stage IV Corneal pterygium
Lesion 2mm or more into corneaInvasion of granulation tissueZone of dellenStocker’s lineInfiltration of corneal nerves- pain
Lesion b/w epithelium and bowman
Mixed proliferative and degeneration
![Page 22: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/22.jpg)
Stage V
Compound pterygium
Induced astigmatismSymptoms more frequent and severe
Lesion extended into stroma
Mixed proliferative and degeneration
Proliferation- Small lymphocytes and plasma cellsDegeneration- Swirls of type I collagen
![Page 23: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/23.jpg)
Fuch’s patches. Stocker’s line. Hood. Head. Body. Base. Superior edge. Inferior edge.
Parts of pterygium
![Page 24: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/24.jpg)
Parts of pterygium
![Page 25: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/25.jpg)
Progressive: thick fleshy marked vascularity.It has opaque infitrative spot known as cap.Stocker’s line.
Atrophic/stationary: thin attenuated poor vascularity no cap.
Clinical types of pterygium
![Page 26: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/26.jpg)
Clinical types
Progressive pterygium Atrophic pterygium
![Page 27: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/27.jpg)
Stocker’s line
![Page 28: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/28.jpg)
Primary double pterygium.
Recurrent pterygium.
Pseudopterygium.
Malignant pterygium(rare):recurrent
pterygium with restriction of ocular
movements.
Other types
![Page 29: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/29.jpg)
Double pterygium involving the visual axis
![Page 30: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/30.jpg)
Asymptomatic Foreign body sensation Discomfort Congestion(redness) Irritation and grittiness-interference with
precorneal tear film. Interference with vision-obscuring visual axis -inducing astigmatism
Cosmesis.
Signs and symptoms
![Page 31: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/31.jpg)
Type 1: extends <2mm on the cornea.
Type 2: 4mm of cornea is involved.
Type 3: encroaches onto >4mm of cornea and involves visual axis.
Signs
![Page 32: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/32.jpg)
Pseudopterygium
Most often hx of previous infective, chemical, thermal, or traumatic injury to the cornea.May occur at multiple locations and is not restricted to the 3 and 9 o'clock (interpalpebral) positions.
-Slit-lamp examination: reveals lesion to be adhesion of a fold of conjunctiva, which has occurred as a response to a previous peripheral corneal ulcer/inflammation.-Lesion typically only fixed at its apex to the cornea so that a probe may be passed underneath its body at the limbus, while a true pterygium adheres to the underlying cornea throughout its length. Thinning of the underlying cornea may be seen at its head.
Differential diagnosisCondition Signs and symptoms Tests
![Page 33: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/33.jpg)
Pinguecula Does not encroach on the cornea.
Slit-lamp examination: reveals exact extent and nature of lesion. A pingueculum is limited to limbus and conjunctiva and does not encroach onto the cornea.
Marginal keratitis Associated with blepharitis. Infiltrate on corneal surface is separated by a clear zone from the limbus. Occur at 2, 4, 8, and 10 o'clock position. Does not have typical pterygium shape. Often superior and inferior.
Corneal swab/scraping: microscopy and culture positive for infecting organism, but infecting organisms are often not detected, as many cases are due to an inflammatory reaction to staphylococcal proteins
![Page 34: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/34.jpg)
Corneal micropannus Hx of trachoma or lack of corneal oxygenation due to excessive contact lens wear.
Slit-lamp examination: reveals encroachment of fine blood vessels onto corneal surface.
Conjunctival carcinoma in situ/ bowens epithlioma.
Rare. Does not have typical pterygium shape. Not restricted to the 3 and 9 o'clock (interpalpebral) positions and can occur at any position on the cornea.
Slit-lamp examination: gelatinous-appearing mass.Biopsy: cytological features of a squamous cell carcinoma, but the basal membrane of the epithelium remains intact.
![Page 35: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/35.jpg)
Squamous cell carcinoma
Rare. Does not have typical pterygium shape. Not restricted to the 3 and 9 o'clock (interpalpebral) positions and can occur at any position on the cornea. May arise from a pterygium, carcinoma in situ, or de novo.
Slit-lamp examination: surface may appear keratinised and friable.Biopsy: well-differentiated squamous cell carcinoma with invasion of the basal membrane.
Limbal dermoid Benign choriostomatous tissue. MC site:inferior temporal quadrant.
Histology contains abberant tissue like epidermal appendages,connective tissue,skin,fatmuscle teeth.
![Page 36: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/36.jpg)
Symptomatic patients- Tear substitutes Inflammation- Topical steroids
Sunglasses- to reduce UV exposure and decrease growth stimulus
Medical Treatment
![Page 37: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/37.jpg)
1. Extension to the visual axis and induced astigmatism.
2. Recurrent irritation.
3. Cosmetic- patient should be explained there is fairly high risk of recurrence, which may be more unsightly.
Indications for surgery
![Page 38: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/38.jpg)
Free conjunctival autograft for primary and recurrent pterygium.
Pre op evaluation:
1. Evaluation of pterygium.
2. Evaluation of superior bulbar conjunctiva.
3. Pre op preparation.
4. Anaesthesia and sedation.
Surgical technique
![Page 39: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/39.jpg)
Preparation and drape.
Place anaesthetic drops or topical vasoconstrictor.
Ask patient to look opposite side of pterygium.
Surgical technique
![Page 40: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/40.jpg)
Pterygium Excision Goal: Achieve a normal, topographically
smooth ocular surface Dissect a smooth plane toward the
limbus Preferable to dissect down to bare
sclera at limbus Bare sclera = remove loose Tenon’s
layer and leave episcleral vessels intact
![Page 41: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/41.jpg)
![Page 42: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/42.jpg)
![Page 43: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/43.jpg)
Mechanism of action: it acts forming a fibrin clot between graft and host tissue.
Advantages : decreases the post op pain. reduces the surgical time as
well as recurrence rate.Disadvantage : not FDA approved. graft dehiscence. infection, discomfort.Recurrence rate: less as compared to suture.
Fibrin sealant and conjunctival auto graft
![Page 44: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/44.jpg)
Avoid exposure to sunlight.
Use of dark sun glasses.
Topical steroid antibiotic drops, topical NSAIDS, artificial tears.
POD3/5 graft acquires redness.
Post operative care
![Page 45: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/45.jpg)
Complete healing expected between 6-8weeks.
Topical medications should be tapered. Lubricants should remain for 3months.
Instruction to patient: avoid exposure to sunlight.
![Page 46: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/46.jpg)
Graft failure. Granuloma formation. Conjunctival infection. Suture detachment. Delayed healing. Recurrence.
Complications
![Page 47: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/47.jpg)
Bare sclera technique:-recurrence:5-68%(primary)35-82%(recurrent)
Other surgical methods
![Page 48: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/48.jpg)
Simple closure: recurrence 45-69%
![Page 49: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/49.jpg)
Sliding flap: recurrence 45-69%
![Page 50: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/50.jpg)
Rotational flap: recurrence 4-6%
![Page 51: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/51.jpg)
Subconjunctival scarring limitation of movements diplopia.
Disinsertion of medial rectus muscle.
Scleral perforation.
Corneal irregularity due to deep stromal excision.
Complications
![Page 52: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/52.jpg)
Pterygium Recurrence Growth of fibrovascular tissue across the
limbus onto cornea after initial removal.
Excludes persistence of deeper corneal vessels and scarring which may remain even after adequate removal.
Bunching of conjunctiva and formation of parallel loops of vessels, which aim almost like an arrowhead at the limbus, usually denotes a conjunctival recurrence.
![Page 53: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/53.jpg)
Proposed Recurrence Grading System
Grade 1 – normal appearing operative site.
Grade 2 – fine episcleral vessels in the site extending to the limbus.
Grade 3 – additional fibrous tissues in site.
Grade 4 – actual corneal recurrence.
![Page 54: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/54.jpg)
AIM: To reduce recurrence.1. Corticosteroids- post operative use of
topical steroids can reduce inflammatory reaction and revascularization at the operative site.
2. No significant role in prevention of recurrence.
Adjunctive therapy
![Page 55: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/55.jpg)
Antibiotic and antineoplastic properties.
Blocks the DNA synthesis.
Concentration: 0.02%
Use: intraoperative to the area of resection
with sponge for 2min followed by irrigating
with balanced salt solution.
Mitomycin C
![Page 56: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/56.jpg)
Side effects: pyogenic granuloma dellen of sclera. perforation of eye. glaucoma. cataract. corneal edema. Recurrence: 3-25% (intraoperative) 5-54%(postoperative)
![Page 57: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/57.jpg)
Post operative period LCAG MMC 3 month 1 - 6 month 1 2 12 month - 1 18 month - - Total 02 (4%) 03 (6%)
Comparison of recurrence rate
![Page 58: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/58.jpg)
Nitrogen mustard alkylating agent. antimitotic property. Radiomimetic- obliterates vascular
endothelial cells. Dose:1:2000 every 3 hours for 6 weeks. Used in bare sclera method. Complication: scleral thinning. Recurrence:10-16%
Thiotepa
![Page 59: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/59.jpg)
Antiproliferative Inhibits thymidylate synthetase, thus
inhibits DNA. Only cells in the synthesis phase are
affected, allowing the remaining cells to continue to proliferate after exposure to 5-FU.
5-fluorouracil
![Page 60: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/60.jpg)
Immunosuppresant drug. Dose: 0.05% topical for 3 months following
pterygium excision.
Safe and effective.
Low recurrence rate(3.4%)
Cyclosporine A
![Page 61: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/61.jpg)
Inhibit neovascularisation. Stop the progression or prevent the
recurrence.
Case reported by Wu and co workers.Topical bevacizumab eye drops 25mg/ml
4times for 3weeks. No recurrence in 1year follow up period.
Bevacizumab
![Page 62: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/62.jpg)
Reduces mitosis in rapidly dividing vascular endothelial cells.
Dose : 15Gy units in single or divided doses.
Recurrence: 4.3%-35% with bare sclera or simple conjunctival closure.
Complications: scleral necrosis endophthalmitis cataract formation. conjunctival telangiectasia.
Beta radiation
![Page 63: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/63.jpg)
The area of bare scleral was covered with amniotic membrane, which was oriented with the basement membrane side up.
The amniotic membrane was sutured through the episcleral tissue to the edge of the conjunctiva along the bare sclera border with 7-8 interrupted 8-0 Vicryl sutures.
The eye was patched.
Amniotic membrane.
![Page 64: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/64.jpg)
Amniotic membrane application after pterygium excision
![Page 65: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/65.jpg)
Useful in:
very large conjunctival defects. To preserve superior conjunctiva for future
glaucoma surgery.
Advantages: faster healing rate less discomfort. lower recurrence rate(2% in 1year follow up)
![Page 66: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/66.jpg)
ANECORTANE ACETATE:
Angiostatic steroid: Inhibits the blood vessel’s.
Topical 1% have inhibitory effect on pterygium regrowth following recurrenr pterygium excision.
Under trial
![Page 67: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/67.jpg)
Surgical and medical management of pterygium-Ashok garg.
Pterygium-a practical guide to management,L. Alfred andeze.
Kanski clinical ophthalmology.
References
![Page 68: Pterygium and its management](https://reader036.fdocuments.net/reader036/viewer/2022081717/554b7d4db4c90561588b49a1/html5/thumbnails/68.jpg)
THANK YOU